share_log

维亚生物涨超25%,复星医药涨近8%,获准仿制默沙东新冠口服药

Weiya Bio rose by more than 25%, Shanghai Fosun Pharmaceutical increased by nearly 8%, and was allowed to imitate Merck & Co Inc Xinguan to take medicine orally.

Breakings ·  Jan 21, 2022 09:41
Weiya creatures rose by more than 25%, and Shanghai Fosun Pharmaceutical by nearly 8%. Drug Patent Pool Organization (Medicines Patent Pool, MPP) announced that it has signed agreements with 27 generic drug manufacturers, and a total of 5 Chinese pharmaceutical companies have been shortlisted in the agreement list. Shanghai Fosun Pharmaceutical, Borey Pharmaceuticals, Shijiazhuang Longze Pharmaceutical and Shanghai Diseno are licensed to produce both Molnupiravir APIs and finished drugs, while Longhua Pharmaceuticals, a subsidiary of via Biology, is allowed to produce Molnupiravir APIs.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment